Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications

SAN CARLOS, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced release of an abstract that will be presented in a poster at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress from September 8 -12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: Details of the poster are as follows:

  • Title: Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma
  • Author: L. Karyampudi et al.
  • Date/Time: Saturday, September 9, 2017 from 13:15-14:15 local time
  • Location: Hall 8
  • Abstract Number: 1017P

“As we explore potential utilization of TIL in treatment of multiple cancer types, we present data at ESMO that demonstrate the ability to produce TIL from lymphoma that have similar functionality as TIL generated from melanoma, giving us reason to further explore the potential of our TIL cell therapy for lymphoma patients in the future,” said Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Iovance Biotherapeutics. “Leveraging our experience in TIL generation from solid tumors to blood-born cancers is a natural extension of our learnings to date. We are exploring potential collaborations with lymphoma experts to supplement our research efforts. The data to be presented at ESMO is indicative of our efforts in becoming a leader in TIL treatment for a variety of tumor types.”

About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information.

About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company’s lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please

Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. The forward-looking statements include risks and uncertainties, relating to the Company’s ability to advance its global development programs and the efficacy of its immune-oncology TIL therapies.  A further list and description of the Company’s risks, uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

CONTACT: Investor Relations Contact: 
Sarah McCabe
Stern Investor Relations, Inc.

Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting